Share:
Overview
Body
ACGSD JUNE PROGRAM: LIFESCIENCES
Mast Therapeutics Completes Merger with Savara
In January of 2017, Mast Therapeutics, Inc., a publicly traded biopharmaceutical
company, and Savara, Inc., a privately-held emerging specialty pharmaceuticalcompany, announced a definitive merger agreement. On April 27th,
2017 the transaction closed and common stock in Savara, Inc. (NASDAQ: SVRA)
commenced trading the following day on the Nasdaq Capital Market. In connection
with the closing of the merger, Mast Therapeutics effected a reverse split of
its common stock.
biopharmaceutical company and leveraging the MAST (Molecular Adhesion and
Sealant Technology) platform, derived from over two decades of clinical,
nonclinical and manufacturing experience to develop MST-188, its lead product
candidate.
Brian Culley - Past CEO and Director, Mast Therapeutics
Larry Nishnick, - Partner Corporate & Securities Practice, DLA Piper LLP (US)
MODERATOR:
David Crean-Managing Director Objective Capital Partners
Biographies:
Brian Culley - Past CEO and Director, Mast Therapeutics
Mr.
Culley served as Mast's Chief Executive Officer from February 2010 until its
merger with Savara, Inc. in April 2017. He led the acquisition of four private
companies and raised in excess of 150M. He was a member of Mast's board
of directors since December 2011. He served as Mast's principal executive
officer since February 2009. From January 2007 to February 2010, he served as
Mast's Chief Business Officer and Senior Vice President, from February 2006 to
January 2007, he served as Mast's Senior Vice President, Business Development,
and, from December 2004 to February 2006, he served as Mast's Vice President,
Business Development.
From 2002 until 2004, Mr. Culley managed all strategic collaborations and licensing agreements for Immusol, Inc. in San Diego, where his most recent title was Director of Business Development and Marketing. From 1999 until 2000, he was a licensing and marketing associate at the University of California, San Diego, department of technology transfer & intellectual property services and from 1996 to 1999, he was a research associate for Neurocrine Biosciences, Inc. Mr. Culley has 25 years of experience in the life science industry. He received a B.S. in biology from Boston College, a masters in biochemistry and molecular biology from the University of California, Santa Barbara and an M.B.A. from The Johnson School of Business at Cornell University.
Larry Nishnick - Partner Corporate & Securities Practice, DLA Piper LLP (US)
Larry’s experience is extensive with deals ranging from angel investments to multi-billion dollar acquisitions. His recent representation of companies includes QUALCOMM, World Wresting Entertainment (WWE), Live Nation Worldwide, The Coca-Cola Company, ViaSat, Lufthansa, Provide Commerce, Jack-in-the-Box, CrossFit, Barclays Bank and a vast number of private emerging growth technology companies. Larry's recent representation of companies in the life sciences and healthcare sectors includes NuVasive Life Technologies, BioFire Diagnostics, bioMérieux, Neothetics, Cypher Genomics, Cytori Therapeutics, Mast Therapeutics, Halozyme Therapeutics, Epic Sciences, BiologicTx and a number of emerging growth companies in the therapeutics, diagnostics, aesthetics, genomics and healthcare industries.
David Crean -Managing Director Objective Capital Partners
David H. Crean, Ph.D is a Managing Director at Objective Capital Partners where he leads the firm’s life science investment banking transactions. Dr. Crean has in excess of 20 years of life sciences R&D and corporate development transactional experience in the pharmaceutical industry where he was responsible for leading mergers, acquisitions, licensing and collaborations, and establishing corporate strategy. David’s transaction experience in the life sciences sector includes sell-side, buy-side, licensing and capital raising activities. He has supported company and client engagements in both U.S. domestic and foreign transactions including Japan, China and Europe.
SPONSORS:
BDO, Departure, & Procopio
REGISTRATION OPENS SOON
ACGSD Members & ACGSD Sponsors 0
Members of Other Chapters 75
Non-Members & Guests 95
Questions:
Contact Executive Director Judy Susser-Travis, CMP, CMM at acgsandiego@acg.org or 619 741 7247
Contact Executive Director Judy Susser-Travis, CMP, CMM at acgsandiego@acg.org or 619 741 7247
Hosted by: ACG
Chapter
San Diego
